And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

VIGL Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 33.45%

Insider Buying (Last 12 Months): $15,000.00

Insider Selling (Last 12 Months): $0.00

Vigil Neuroscience Insider Trading History Chart

Vigil Neuroscience Share Price & Price History

^$2.60

▲ +0.02 (0.78%)

As of 04/26/2024 11:46 AM ET

Days: 30 | 90 | 365

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Vigil Neuroscience Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2023	Ivana Magovcevic-Liebisch	CEO	Buy	4,000	$3.75	$15,000.00	207,687
11/18/2022	Spyros Papapetropoulos	Insider	Sell	300	$14.00	$4,200.00	4,000
5/16/2022	Clay Thorp	Director	Buy	21,802	$2.76	$60,173.52	1,541,137
5/5/2022	Evan Thackaberry	SVP	Buy	1,500	$4.00	$6,000.00	1,500
5/3/2022	Christopher Verni	General Counsel	Buy	4,000	$3.77	$15,080.00	4,000
5/3/2022	Ivana Magovcevic-Liebisch	CEO	Buy	1,000	$3.94	$3,940.00	203,687
3/28/2022	Clay Thorp	Director	Buy	3,000	$7.20	$21,600.00

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

SEC Filings (Institutional Ownership Changes) for Vigil Neuroscience (NASDAQ:VIGL)

83.64% of Vigil Neuroscience stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vigil Neuroscience Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
1/30/2024	Strs Ohio	8,200	$27K	0.0%	N/A	0.023%
12/6/2023	Citigroup Inc.	64,303	$0.35M	0.0%	-6.9%	0.179%
11/15/2023	Laurion Capital Management LP	10,839	$58K	0.0%	-89.1%	0.030%
11/14/2023	Deerfield Management Company L.P. Series C	1,827,400	$9.85M	0.2%	-10.9%	5.093%
11/14/2023	PEAK6 Investments LLC	23,796	$0.13M	0.0%	+66.0%	0.066%
8/14/2023	Deep Track Capital LP	1,773,409	$16.67M	0.8%	-12.4%	4.944%
8/11/2023	Artal Group S.A.	1,911,191	$17.97M	0.6%	-14.8%	5.328%
8/4/2023	American International Group Inc.	7,734	$73K	0.0%	N/A	0.022%
8/2/2023	Bank of Montreal Can	73,243	$0.73M	0.0%	N/A	0.205%
5/4/2023	Barclays PLC	104,248	$1.02M	0.0%	-1.6%	0.292%
2/14/2023	683 Capital Management LLC	15,092	$0.19M	0.0%	N/A	0.042%
2/13/2023	Artal Group S.A.	2,243,352	$28.04M	1.6%	-1.8%	6.305%
2/9/2023	Citigroup Inc.	93,927	$1.17M	0.0%	+38.8%	0.264%
2/1/2023	Bank of Montreal Can	58,100	$0.73M	0.0%	N/A	0.163%
11/15/2022	BVF Inc. IL	1,813,633	$16.50M	0.7%	N/A	5.097%
11/15/2022	Citadel Advisors LLC	2,166,467	$19.72M	0.0%	+0.1%	6.089%
11/14/2022	Ergoteles LLC	28,533	$0.26M	0.0%	N/A	0.101%
11/14/2022	Altium Capital Management LP	15,788	$0.14M	0.1%	N/A	0.056%
8/15/2022	Laurion Capital Management LP	130,200	$0.34M	0.0%	N/A	0.461%
5/16/2022	Deep Track Capital LP	389,141	$2.74M	0.2%	N/A	1.377%
5/12/2022	Artal Group S.A.	1,121,191	$7.88M	0.3%	N/A	3.966%
5/5/2022	New York State Common Retirement Fund	8,500	$60K	0.0%	N/A	0.030%

Data available starting January 2016

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.60

$2.58

$2.66

50 Day Range

MA: $3.13

$2.58

$3.48

52 Week Range

Now: $2.60

$2.53

$11.11

Volume

7,288 shs

Average Volume

97,230 shs

Market Capitalization

$97.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Who are the company insiders with the largest holdings of Vigil Neuroscience?: Vigil Neuroscience's top insider shareholders include:
Clay Thorp (Director)
Ivana Magovcevic-Liebisch (CEO)
Christopher Verni (General Counsel)
Spyros Papapetropoulos (Insider)
Evan Thackaberry (SVP)
Learn More about top insider investors at Vigil Neuroscience.

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here